European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - nicorandil - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

somex pharma - nicorandil - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

somex pharma - nicorandil - oral tablet - 20mg

Israel - English - Ministry of Health

novartis israel ltd - glyceryl trinitrate - patches - glyceryl trinitrate 25 mg/patch - glyceryl trinitrate - glyceryl trinitrate - prophylaxis of angina pectoris.

Israel - English - Ministry of Health

novartis israel ltd - glyceryl trinitrate - patches - glyceryl trinitrate 25 mg/patch - glyceryl trinitrate - glyceryl trinitrate - prophylaxis of angina pectoris.

Israel - English - Ministry of Health

novartis israel ltd - glyceryl trinitrate - patches - glyceryl trinitrate 50 mg/patch - glyceryl trinitrate - glyceryl trinitrate - prophylaxis of angina pectoris.

Israel - English - Ministry of Health

novartis israel ltd - glyceryl trinitrate - patches - glyceryl trinitrate 50 mg/patch - glyceryl trinitrate - glyceryl trinitrate - prophylaxis of angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 2.5 mg) - tablet, uncoated - excipient ingredients: mannitol; calcium hydrogen phosphate dihydrate; magnesium stearate; maize starch - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 21.78 mg (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.